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A B S T R A C T
Objectives: In a phase Ib trial, afatinib plus cetuximab demonstrated promising clinical activity (objective re-
sponse rate [ORR]: 29%; median progression-free survival [PFS]: 4.7 months) in patients with epidermal growth
factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) with acquired resistance to erlotinib
or geﬁtinib. Here, a separate cohort exploring afatinib plus cetuximab after progression on afatinib is reported.
Materials and methods: Patients with EGFR mutation-positive NSCLC who progressed on erlotinib or geﬁtinib
received afatinib 40 mg daily until progression, followed by afatinib daily plus cetuximab 500 mg/m2 every 2
weeks until progression or intolerable adverse events (AEs). Endpoints included safety, ORR, and PFS.
Results: Thirty-seven patients received afatinib monotherapy. Two (5%) patients responded; median PFS was 2.7
months. Thirty-six patients transitioned to afatinib plus cetuximab. Four (11%) patients responded; median PFS
was 2.9 months. Median PFS with afatinib plus cetuximab for patients who received afatinib monotherapy for
≥12 versus< 12 weeks was 4.9 versus 1.8 months (p= 0.0354), and for patients with T790M-positive versus
T790M-negative tumors was 4.8 versus 1.8 months (p= 0.1306). Fifty percent of patients receiving afatinib plus
cetuximab experienced drug-related grade 3/4 AEs. The most frequent drug-related AEs (any grade) were
diarrhea (70%), rash (49%), and fatigue (35%) with afatinib monotherapy and rash (69%), paronychia (39%),
and dry skin (36%) with afatinib plus cetuximab.
Conclusion: Sequential EGFR blockade with afatinib followed by afatinib plus cetuximab had a predictable safety
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Epidermal growth factor receptor (EGFR) mutation-positive
(EGFRm+) non-small-cell lung cancer (NSCLC) tumors are extremely
sensitive to the EGFR tyrosine kinase inhibitors (TKIs), erlotinib, geﬁ-
tinib, and afatinib, all of which are approved as ﬁrst-line treatment in
this setting [1–8]. Unfortunately, tumors inevitably develop resistance
to these agents. The most common resistance mechanism is the emer-
gence of the T790M EGFR mutation within exon 20, occurring in ap-
proximately 50% of patients [9–11]. While osimertinib, a third-gen-
eration EGFR TKI, has recently been approved for patients with T790M-
positive (T790M+) NSCLC with progression following EGFR TKI
therapy, treatment options for EGFR TKI-resistant NSCLC remain lim-
ited, especially in patients with T790M-negative (T790M−) tumors
[12].
In contrast to erlotinib and geﬁtinib, which inhibit only EGFR,
afatinib is an ErbB family blocker that irreversibly blocks signaling from
all relevant homo- and hetero-dimers of the ErbB family of receptors
(EGFR, human epidermal growth factor receptor 2 [HER2], ErbB3, and
ErbB4) [13]. The recent phase IIb trial, LUX-Lung 7, demonstrated that
afatinib conferred better progression-free survival (PFS) and time to
treatment failure versus geﬁtinib in patients with previously untreated
NSCLC, suggesting that the broader inhibitory proﬁle of afatinib may
oﬀer advantages in terms of clinical activity in a ﬁrst-line setting [14].
Also, given that ErbB family members have been implicated in the ac-
quired resistance to ﬁrst-generation EGFR TKIs [15,16], and afatinib
has shown inhibitory activity against EGFR T790M/L858R tumors in
preclinical models (albeit at relatively high concentrations) [17], there
was rationale for assessing afatinib monotherapy in patients with EGFR
mutation-positive NSCLC following failure of erlotinib or geﬁtinib.
However, in clinical trials, afatinib conferred only modest response
rates in this setting [18,19]. Nevertheless, afatinib-based combinations
warrant clinical evaluation, due to potential synergy with other agents.
One potential strategy is dual targeting of EGFR [20].
Cetuximab, an anti-EGFR monoclonal antibody, is approved for the
treatment of KRAS wild-type colorectal and head and neck cancers. In
mice harboring tumors with L858R/T790M mutations, afatinib plus
cetuximab resulted in extensive tumor regression greater than what was
observed with either agent alone [20]. We therefore conducted a study
to determine the maximum tolerated dose (MTD), safety, and pre-
liminary eﬃcacy of afatinib plus cetuximab in patients with EGFR-
mutant tumors and acquired resistance to erlotinib/geﬁtinib. We pre-
viously reported that afatinib plus cetuximab in these patients was as-
sociated with an objective response rate (ORR) of 29% [21]. Based on
these data, the National Comprehensive Cancer Network Clinical
Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC, version
3, 2017, state that afatinib plus cetuximab may be considered in pa-
tients with disease progression on EGFR TKI therapy (category 2A
evidence and consensus) [22]. Here, we report pharmacokinetic data
from the afatinib plus cetuximab cohort, and eﬃcacy and safety data
from an additional cohort that was treated with afatinib monotherapy
followed, upon progression, by afatinib plus cetuximab (at the MTD
previously established). Given that afatinib-based combinations have
previously demonstrated activity in patients with acquired resistance to
afatinib monotherapy following≥12 weeks of clinical beneﬁt [19], and
development of T790M is the predominant mechanism of acquired re-
sistance to afatinib [11], we also assessed the eﬃcacy of afatinib plus
cetuximab according to the duration of prior afatinib monotherapy
(< 12 weeks; ≥12 weeks) and T790M status.
2. Materials and methods
2.1. Study design
This open-label, phase Ib study was conducted in three phases: a
dose-ﬁnding phase to identify the MTD of afatinib plus cetuximab, an
expansion phase to evaluate the MTD (previously reported) [21], and a
sequential phase assessing afatinib monotherapy until disease pro-
gression and afatinib plus cetuximab thereafter (Fig. 1). The primary
endpoint was occurrence of dose-limiting toxicities. Secondary end-
points included safety, pharmacokinetics, PFS, ORR, and disease con-
trol rate (DCR).
Upon observation of eﬃcacy in patients treated at MTD (afatinib
40 mg p.o. daily plus cetuximab 500 mg/m2 i.v. every 2 weeks), the
sequential phase was added to assess the safety and antitumor activity
of afatinib with cetuximab in patients with EGFR-mutant NSCLC with
acquired resistance to erlotinib or geﬁtinib, who had progressed on
afatinib monotherapy. Those patients who progressed after at least 12
weeks of disease control on afatinib monotherapy were deﬁned as
having acquired resistance to afatinib.
The study was conducted in compliance with the International
Conference on Harmonization and Good Clinical Practice guidelines
and the protocol was approved by the relevant institutional review
boards. Patients provided written informed consent prior to study
participation.
2.2. Patients
Patients with conﬁrmed stage IIIb/IV NSCLC harboring EGFR mu-
tations associated with EGFR TKI sensitivity or exon 20 insertions or de
novo T790M mutation were eligible. Participants had progressed on
continuous erlotinib/geﬁtinib within 30 days of initiation of study
treatment [23]. Patients had to stop erlotinib/geﬁtinib for ≥3 days
prior to starting afatinib [24]. Additional inclusion criteria were ade-
quate organ function and Eastern Cooperative Oncology Group per-
formance status of 0–2. Exclusion criteria included prior treatment with
EGFR-targeting antibodies, symptomatic brain metastases, interstitial
lung disease, radiotherapy within 2 weeks, and systemic chemotherapy,
hormonal therapy, immunotherapy, or experimental or approved anti-
body/proteins within 30 days of starting study treatment.
2.3. Treatment
Patients received afatinib 40 mg p.o. daily until disease progression
and then continued afatinib with added cetuximab 500 mg/m2 i.v.
given every 2 weeks (patients who had dose reduction during afatinib
monotherapy maintained their afatinib dose). Patients who had re-
ceived afatinib monotherapy in other trials, and progressed after ≥12
weeks, could be enrolled into the combination therapy phase of this
study. Patients received combination therapy within 30 days of pro-
gression on monotherapy with no intervening systemic therapy.
Treatment continued until disease progression, intolerable adverse
events (AEs), study withdrawal, or death. Treatment beyond progres-
sion was allowed at the investigator’s discretion. Management of AEs by
dose reduction was prespeciﬁed. For the MTD (afatinib 40 mg/cetux-
imab 500 mg/m2), on ﬁrst occurrence of grade ≥3 AEs (other than
hypomagnesemia where only cetuximab was to be reduced), cetuximab
was reduced by 100 mg to 400 mg, and on second occurrence, afatinib
and cetuximab were reduced (by 10 mg to 30 mg for afatinib and by
100 mg to 300 mg for cetuximab). Dose reduction below afatinib 30 mg
was not permitted. A maximum of one cetuximab infusion per cycle
could be skipped to allow recovery from drug-related AEs.
2.4. Assessments
EGFRmutation analysis was mandatory prior to study entry and was
undertaken on fresh or archived tumor tissues, in a Clinical Laboratory
Improvement Amendments-certiﬁed laboratory. Re-biopsy following
disease progression while on study was optional. Mutations in exons
18–21 of the tyrosine kinase domain of EGFR were analyzed by poly-
merase chain reaction-restriction fragment length polymorphism-based
assays or direct Sanger sequencing.
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AEs were graded using National Cancer Institute Common
Terminology Criteria for Adverse Events version 3.0 [25]. Tumor as-
sessments, performed by computed tomography at baseline, weeks 4, 8,
and 12, and every 8 weeks thereafter, were assessed by the investigator
according to Response Evaluation Criteria in Solid Tumors version 1.1
[26].
2.5. Pharmacokinetic analysis
Pharmacokinetic analysis focused on afatinib plus cetuximab, and
analyzed patients in the dose-escalation phase and the ﬁrst 24 patients
enrolled in the MTD expansion phase. Blood samples were taken at
predeﬁned intervals from the start of the study to the third treatment
course (see Supplementary Material A1, for the blood sample collection
schedule). Plasma concentrations of afatinib were analyzed by a vali-
dated high performance liquid chromatography–tandem mass spectro-
metry assay with a minimum detection level of 1.25 ng/mL; serum
concentrations of cetuximab were analyzed by a validated enzyme-
linked immunosorbent assay with a minimum detection level of
12500 ng/mL.
Fig. 1. Study design and patient disposition. Abbreviations: AE, adverse event; MTD, maximum tolerated dose; PD, progressive disease; Q2W, every 2 weeks. *Previously reported





AUCτ,ss Area under the concentration–time curve of the analyte in
plasma at steady state over a uniform dosing interval τ
CI Conﬁdence interval
Cmax,ss Maximum measured concentration of the analyte in
plasma at steady state over a uniform dosing interval
CR Complete response
DCR Disease control rate
ECOG PS Eastern Cooperative Oncology Group performance status
EGFR Epidermal growth factor receptor
gCV Geometric coeﬃcient of variation
gMean Geometric mean
HER2 Human epidermal growth factor receptor 2
i.v. Intravenous
MTD Maximum tolerated dose
NCCN National comprehensive cancer network
NE Not evaluable
NSCLC Non-small-cell lung cancer
ORR Objective response rate
PD Progressive disease
PFS Progression-free survival
p.o. Per os (oral administration)
PR Partial response
Q2W Every 2 weeks
SD Stable disease
TKI Tyrosine kinase inhibitor
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2.6. Statistical analysis
Safety and antitumor activity were assessed in patients with ac-
quired resistance to erlotinib/geﬁtinib who received ≥1 dose of afa-
tinib, and in patients who received≥1 dose of afatinib and cetuximab.
Descriptive statistics were used. Exploratory analyses of the sequential
phase summarized antitumor activity and PFS according to the duration
of previous afatinib monotherapy (≥12 weeks or< 12 weeks) and




A total of 201 patients were enrolled and 171 were treated across
the three study phases. Of these, 10 were treated in the dose-ﬁnding
phase (including six treated at MTD of afatinib 40 mg daily plus ce-
tuximab 500 mg/m2 every 2 weeks) and 120 were treated at MTD in the
expansion phase (previously reported) [21]. For the sequential phase,
37 patients received afatinib monotherapy; 32 entered the combination
phase. Four patients were enrolled into the combination phase from
other afatinib monotherapy trials (and had previously progressed on
erlotinib/geﬁtinib; Fig. 1).
Patients in the sequential phase had received prior EGFR TKI
treatment for a median of 1 year (range,< 1–6; Table 1). Approxi-
mately 70% of patients had Del19-positive (Del19+) tumors; one pa-
tient had an exon 20 insertion. T790M status was known for all patients
in the sequential phase: approximately 55% were T790M+ and 45%
were T790M−(Table 1).
3.2. Eﬃcacy
Median time on treatment was 2.8 months (range, 0.2–14.7) with
afatinib monotherapy. Two of 37 patients (5%) achieved a conﬁrmed
objective response by week 4 and 12, respectively (conﬁrmed partial
responses [PRs]; Table 2). Median duration of response was 3.9 months
(range, 3.8–3.9). One of the two patients who responded had a T790M
+ tumor. DCR on afatinib monotherapy was 57%.
Thirty-two patients from the monotherapy phase and four patients
from other afatinib trials were treated in the combination phase.
Median time on treatment was 2.6 months (range, 0.5–21.6). Four
patients (11.1%) achieved a conﬁrmed objective response (all PRs;
Table 2), three of whom had acquired resistance to afatinib mono-
therapy. Two PRs were achieved by week 4, the third by week 8, and
the fourth after week 32. Median duration of response was 5.7 months
(range, 3.7–8.3). None of the patients who responded during the
combination phase had responded to afatinib monotherapy. The ORR
was numerically higher in patients who received ≥12 weeks
versus< 12 weeks of prior afatinib monotherapy (15.8% and 5.9%;
Table 2) and in patients who had T790M+ versus T790M− tumors
(20.0% and 0.0%; Table 2). Overall, the DCR in patients who received
combination therapy was 50.0%. The DCR according to duration of
prior afatinib monotherapy was 57.9% (≥12 weeks) and 41.2% (<12
weeks). The DCR according to T790M status was 60.0% (T790M+) and
37.5% (T790M−), respectively. Outcomes following combination
therapy were similar in patients whose tumors were Del19+ (n= 25;
DCR = 48.0%; ORR = 12.0%) and L858R+ (n= 9; DCR = 44.4%;
ORR = 11.1%).
Median PFS was 2.7 months (95% conﬁdence interval [CI]: 1.1–3.7)
and 2.9 months (95% CI: 1.8–4.8) in the monotherapy and combination
phases, respectively (Table 2, Fig. 2). PFS on combination therapy was
signiﬁcantly longer in patients who received ≥12 weeks versus< 12
weeks of afatinib monotherapy (4.9 months and 1.8 months;
p = 0.0354; Table 2). PFS in patients who had T790M+ versus
T790M−tumors was 4.8 months and 1.8 months, respectively
(p= 0.1306; Table 2). Median PFS among patients with Del19+ tu-
mors was 2.7 and 2.9 months with afatinib monotherapy and afatinib
plus cetuximab, respectively. For those with L858R+ tumors, median
PFS was 3.6 and 1.8 months with afatinib monotherapy and afatinib
plus cetuximab, respectively. One patient with an exon 20 insertion
who received afatinib plus cetuximab had stable disease at weeks 4 and
8; the patient died from an unrelated stroke on day 107. PFS status for
individual patients is shown in Fig. 3.
Given the signals of clinical activity in patients who had T790M+
tumors, or had received ≥12 weeks of afatinib monotherapy, we un-
dertook further exploratory analysis assessing outcomes in patients
with T790M+ tumors and/or≥12 weeks of afatinib monotherapy (see
Supplementary Table S1, for response and PFS according to acquired
resistance and T790M status). Despite small patient numbers, PFS and
ORR were numerically higher in the T790M+/≥ 12 weeks and T790M
+/ < 12 weeks groups compared with the T790M−/ < 12 weeks
Table 1
Patient characteristics at baseline.
Sequential phase






Median (range) 58 (34–80) 58 (27–80)
Female gender, no. (%) 23 (62.2) 22 (61.1)
Race, no. (%)
Asian 5 (13.5) 5 (13.9)
Black/African American 1 (2.7) 1 (2.8)
White 31 (83.8) 30 (83.3)
Smoking history, no. (%)
Never smoked 25 (67.6) 25 (69.4)
≤15 pack years 7 (18.9) 7 (19.4)
> 15 pack years 2 (5.4) 2 (5.6)
Missing 3 (8.1) 2 (5.6)
ECOG PS, no. (%)
0 9 (24.3) 8 (22.2)
1 or 2 28 (75.7) 28 (77.8)
Time since diagnosis of
NSCLC,a years
Median (range) 2 (1–15) 2 (1–15)
Duration of prior EGFR
TKI,b years
Median (range) 1 (< 1–6) 1 (< 1–6)
Prior chemotherapy, no.
(%)
0 or 1 line 25 (67.6) 24 (66.7)
≥2 lines 12 (32.4) 12 (33.3)
EGFR mutation status, no.
(%)
Del19+ 26 (70.3) 25 (69.4)
L858R+ 9 (24.3) 9 (25.0)
Other 2 (5.4)c 2 (5.6)d
T790M status, no. (%)
T790M+ 20 (54.1) 20 (55.6)
T790M– 17 (45.9) 16 (44.4)
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR,
epidermal growth factor receptor; NSCLC, non-small cell lung cancer; TKI, tyrosine kinase
inhibitor.
a Available for 34 patients in the monotherapy phase and 33 patients in the combi-
nation therapy phase of the sequential phase, respectively.
b Maximum duration if patients received more than one prior EGFR TKI regimen.
c One patient had a de novo T790M mutation (and did not participate in the combi-
nation phase), the other patient had G719C and L861Q mutations.
d One patient (who was enrolled from another trial following progression on afatinib
monotherapy) had an exon 20 insertion, the other patient had G719C and L861Q muta-
tions.
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group. Furthermore, in the T790M−/≥ 12 weeks group, median PFS
was 10.1 months and the DCR was 50%. Notably, two patients in this
group demonstrated encouraging PFS of 10.1 and 11.1 months, re-
spectively (Fig. 3), indicating that absence of T790M+ does not pre-
clude prolonged PFS as long as afatinib confers beneﬁt for≥12 weeks.
3.3. Safety
Ninety-seven percent of patients receiving afatinib monotherapy
reported drug-related AEs; 35% experienced grade 3 events and no
drug-related grade 4/5 AEs were reported. The most frequent drug-re-
lated AEs (any grade) included diarrhea (70%), rash (49%), fatigue
(35%), and stomatitis (27%) (Table 3).
In the combination phase, 94% of patients reported drug-related
AEs, with 50% experiencing grade 3/4 AEs (16 [44%] reported grade 3
AEs; 2 [6%] reported grade 4 AEs). There were no drug-related grade 5
AEs. The most frequent drug-related AEs (any grade) were rash (69%),
paronychia (39%), dry skin (36%), and diarrhea (33%).
Drug-related serious AEs were reported in two patients receiving
afatinib monotherapy (grade 3 decreased appetite and diarrhea;
grade<3 dehydration, nausea, and vomiting) and one patient re-
ceiving afatinib plus cetuximab (grade 3 chills and pyrexia).
Five patients (14%) receiving afatinib monotherapy required dose
reduction for AEs; three patients (8%) reported grade 3 events, in-
cluding diarrhea (5%) and rash (3%). These patients entered into the
combination phase at a reduced starting dose of afatinib 30 mg/day
plus cetuximab 500 mg/m2. Eight patients (22%) receiving afatinib and
cetuximab required dose reduction due to AEs, primarily due to rash
(14%). Treatment discontinuation due to drug-related AEs was neces-
sary in three patients (8%) receiving afatinib plus cetuximab (cough,
rash [grade 4], and skin infection [grade 3]). There were no treatment
discontinuations during the afatinib monotherapy phase.
3.4. Pharmacokinetics
Afatinib exposure was higher in the afatinib 40 mg plus cetuximab
250 mg/m2 group versus the afatinib 40 mg plus cetuximab 500 mg/m2
group. However, considering the large diﬀerence in patient numbers
and variability between groups, afatinib pharmacokinetic parameters
were considered similar in the presence of diﬀerent cetuximab doses
(see Supplementary Fig. S1 and Supplementary Table S2, for pharma-
cokinetic parameters of afatinib alone and with cetuximab). Observed
cetuximab serum concentrations were compared with historical data
using a population pharmacokinetic model-based approach. There was
no evidence that afatinib had a clinically relevant eﬀect on exposure to
cetuximab (see Supplementary Material A2 and Supplementary Table
S3, for observed and simulated cetuximab serum concentrations).
4. Discussion
Sequential use of afatinib monotherapy followed by afatinib plus
cetuximab was feasible in patients with EGFR mutation-positive NSCLC
with acquired resistance to erlotinib or geﬁtinib. In particular, patients
with T790M+ tumors and/or those who received ≥12 weeks of afa-
tinib monotherapy demonstrated signals of clinical activity to this re-
gimen. Overall, treatment discontinuations due to treatment-related
AEs were low. Pharmacokinetic data suggested no relevant drug–drug
interactions between afatinib and cetuximab.
Afatinib monotherapy was associated with an ORR of 5%, DCR of
57%, and median PFS of 2.7 months in patients with acquired re-
sistance to erlotinib/geﬁtinib. These results are consistent with those in
the phase IIb/III LUX-Lung 1 trial, which enrolled patients with ad-
vanced NSCLC who had received prior chemotherapy and progressed
on erlotinib or geﬁtinib. The ORR on afatinib was 7%; median PFS was
3.3 months [18]. Following progression on monotherapy, afatinib plus
cetuximab led to an ORR of 11%, DCR of 50%, and median PFS of 2.9
months. In the previously reported upfront combination phase of our
study, afatinib plus cetuximab resulted in an ORR of 29%, DCR of 89%,
and median PFS of 4.7 months [21]. However, it is not possible to
compare the relative eﬃcacy of afatinib plus cetuximab in the se-
quential and combination cohorts of the study, given diﬀerences in the
patient populations.
Overall incidence of drug-related AEs was similar when afatinib and
cetuximab were used as an upfront combination (99% all grades and
46% grade 3/4) [21] or after afatinib (94% all grades and 50% grade 3/
4), as were discontinuations due to drug-related AEs (13% with upfront
combination [21] and 8% after afatinib). However, incidence of drug-
related diarrhea and rash was lower with the sequential regimen (33%
and 69% all grades) than the combination regimen (71% and 90% all
grades) [21]. This may have been partly because patients in the
Table 2
Eﬃcacy in the dose-escalation phase and in the monotherapy and combination therapy phases of the sequential phase.













DCR, no. (%) 21 (56.8) 18 (50.0) 11 (57.9) 7 (41.2) 0.3189 12 (60.0) 6 (37.5) 0.0512*
ORR, no. (%) 2 (5.4) 4 (11.1) 3 (15.8) 1 (5.9) 0.3630 4 (20.0) 0 (0) 0.0823**
CR 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
PR 2 (5.4) 4 (11.1) 3 (15.8) 1 (5.9) 4 (20.0) 0 (0)
SD 19 (51.4) 14 (38.9) 8 (42.1) 6 (35.3) 8 (40.0) 6 (37.5)
PD 13 (35.1) 11 (30.6) 4 (21.1) 7 (42.1) 3 (15.0) 8 (50.0)








3.9 (3.8–3.9) 5.7 (3.7–8.3) 7.4 (3.9–8.3) 3.7 (3.7–3.7) 5.7 (3.7–8.3) –
Median PFS, months
(95% CI)
2.7 (1.1–3.7) 2.9 (1.8–4.8) 4.9 (1.6–10.1) 1.8 (0.9–4.5) 0.0354 4.8 (1.8–5.9) 1.8 (0.9–4.5) 0.1306***
Abbreviations: CI, conﬁdence interval; CR, complete response; DCR, disease control rate; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PFS, progression-free
survival; PR, partial response; SD, stable disease.
* Logistic regression p value.
** Fishers exact test p value.
*** Log-rank test p value.
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sequential phase were able to dose reduce to afatinib 30 mg mono-
therapy and remain on that dose when they received the combination.
Furthermore, in the sequential regimen, patients received afatinib
monotherapy ﬁrst, which was associated with a lower incidence of
drug-related grade 3/4 events than afatinib plus cetuximab (35% vs
50%, respectively). Therefore, sequential treatment may oﬀer an al-
ternative approach for patients for whom achieving a response may not
be as important or where tolerability, particularly rash or diarrhea, may
be a concern. Additionally, for those who have already progressed on
afatinib monotherapy, the addition of cetuximab may oﬀer further
clinical beneﬁt. An ongoing phase II/III trial will provide further in-
formation on the safety of afatinib monotherapy versus afatinib plus
cetuximab in EGFR TKI-naive patients with EGFR mutation-positive
advanced NSCLC (NCT02438722).
Although numbers are small, exploratory analysis suggests that
patients with T790M+ tumors respond better to afatinib plus cetux-
imab than those with T790M tumors following afatinib monotherapy.
Since this trial was conceived and commenced, third-generation EGFR
TKIs such as osimertinib and olmutinib (in South Korea only) have been
approved for the treatment of patients with conﬁrmed T790M muta-
tions and have conferred remarkable activity as second-line therapy in
this setting (ORRs of ∼60%) [27,28]. Given these observations, the
regimen described herein is unlikely to constitute a major treatment
option immediately following acquired resistance to a ﬁrst-line EGFR
TKI in most cases. It may, however, have a role in patients who have
progressed following a third-generation TKI, or cannot tolerate these
agents. Furthermore, observations in this study suggest that presence of
T790M is not a prerequisite for sensitivity to combination therapy; DCR
and PFS were also promising in patients who received ≥12 weeks of
treatment with afatinib monotherapy, regardless of T790M status, with
two patients demonstrating PFS of nearly a year. Furthermore, in the
previous analysis of upfront afatinib plus cetuximab, response rates
were very similar in T790M+ (32%) and T790M−(25%) tumors [21].
Therefore, the combination warrants further evaluation in the T790M−
setting, an area of signiﬁcant unmet medical need.
The mechanism for the eﬃcacy of afatinib plus cetuximab has not been
elucidated but may be because they bind to diﬀerent parts of the receptor
(intracellular and extracellular, respectively) [29]. Afatinib also induces
redistribution of EGFR to the cell surface [30]. The broad ErbB inhibition
of afatinib may be important as HER2 ampliﬁcation has been implicated in
resistance to EGFR TKIs and cetuximab [31]. Interestingly, erlotinib plus
cetuximab failed to produce any objective responses in patients with ac-
quired resistance to erlotinib or geﬁtinib [32].
In conclusion, sequential blockade of ErbB family receptors with afa-
tinib followed by afatinib plus cetuximab had a predictable safety proﬁle
and showed activity in heavily pretreated patients with acquired resistance
to erlotinib or geﬁtinib. Further clinical evaluation of afatinib plus ce-
tuximab is warranted.
Fig. 2. Kaplan–Meier curves of PFS in (A) the monotherapy phase of the sequential phase; (B) the combination phase of the sequential phase; (C) the combination phase of the sequential
phase according to T790M status; (D) the combination portion of the sequential phase according to T790M status and duration of prior afatinib monotherapy (< 12 weeks;≥12 weeks).
CI, conﬁdence interval; PFS, progression-free survival.
Note: symbols on the lines indicate censored patients.
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Fig. 3. Duration of PFS for individual patients on afatinib monotherapy followed by afatinib and cetuximab combination therapy. AR, acquired resistance; PFS, progression-free survival.
*Received afatinib monotherapy in other trials and had ≥12 weeks of beneﬁt.
Table 3
Treatment-related AEs occurring in ≥10% of patients in either the monotherapy or combination phases of the sequential arm.
Afatinib 40 mg monotherapy (n= 37) Afatinib/cetuximab combination therapy (n= 36)
AE, no. (%) Total Grade 3a Grade 4 Total Grade 3b Grade 4
Total with related AEs 36 (97.3) 13 (35.1) 0 34 (94.4) 16 (44.4) 2 (5.6)
Diarrhea 26 (70.3) 2 (5.4) 0 12 (33.3) 0 0
Rash++ 18 (48.6) 1 (2.7) 0 25 (69.4) 7 (19.4) 1 (2.8)
Fatigue+ 13 (35.1) 3 (8.1) 0 10 (27.8) 0 0
Stomatitis+ 10 (27.0) 0 0 4 (11.1) 0 0
Headache 8 (21.6) 2 (5.4) 0 8 (22.2) 2 (5.6) 0
Acne/dermatitis acneiform++ 7 (18.9) 0 0 9 (25.0) 2 (5.6) 0
Nausea 7 (18.9) 0 0 7 (19.4) 0 0
Paronychia+ 7 (18.9) 0 0 14 (38.9) 0 0
Vomiting 6 (16.2) 0 0 2 (5.6) 0 0
Dizziness 5 (13.5) 0 0 2 (5.6) 0 0
Dry skin 5 (13.5) 0 0 13 (36.1) 0 0
Pyrexia 5 (13.5) 0 0 5 (13.9) 1 (2.8) 0
Cough 4 (10.8) 0 0 3 (8.3) 0 0
Decreased appetite 4 (10.8) 1 (2.7) 0 2 (5.6) 0 0
Dyspnea 4 (10.8) 1 (2.7) 0 1 (2.8) 1 (2.8) 0
Epistaxis 4 (10.8) 0 0 2 (5.6) 0 0
Rhinorrhea 3 (8.1) 0 0 4 (11.1) 0 0
Hypomagnesemia 2 (5.4) 0 0 10 (27.8) 0 1 (2.8)
Alopecia 2 (5.4) 0 0 5 (13.9) 0 0
Chills 2 (5.4) 0 0 4 (11.1) 1 (2.8) 0
Pruritus 1 (2.7) 0 0 6 (16.7) 0 0
Dry mouth 0 0 0 4 (11.1) 0 0
Abbreviations: AE, adverse event.
Note: + and ++ indicate grouped terms.
a Additional grade 3 treatment-related events with afatinib monotherapy comprised: back pain, n= 1; hypokalemia, n= 1; hyponatremia, n= 1; upper respiratory tract infection,
n= 1; and syncope, n= 1.
b Additional grade 3 treatment-related events with afatinib and cetuximab combination therapy comprised: blood magnesium decreased, n= 1; hypophosphatemia, n= 2; eyelid
infection, n= 1; hypokalemia, n= 1; hyponatremia, n= 1; neutrophilic dermatosis, n= 1; presyncope, n= 1; and skin infection, n= 1.
L. Horn et al. Lung Cancer 113 (2017) 51–58
57
Funding
This work was supported by Boehringer Ingelheim. No grant
number is applicable.
The sponsor was involved in the trial design and managed the
clinical trial database. Data were collected by the investigators and
were analyzed jointly with the sponsor. All authors, including those
employed by the sponsor, were responsible for data interpretation and
the development of the article, and approved the ﬁnal version for
submission.
Disclosures
Dr Horn reports a consultancy/advisory role with Abbvie, Lilly,
Genentech, Merck, BMS, and Xcovery, and receipt of research funding
from AstraZeneca. Dr Gettinger reports a consultancy/advisory role
with Ariad Pharmaceuticals and BMS and receipt of research funding
from Ariad Pharmaceuticals, BMS, Genentech, Incyte, and Celldex.
Prof. Smit reports a consultancy/advisory role with Lilly and receipt of
research funding from Boehringer Ingelheim, Bayer, Roche, Genentech,
and AstraZeneca. Dr Janjigian reports a consultancy/advisory role with
Lilly and Pﬁzer and receipt of research funding from Boehringer
Ingelheim, Bayer, Lilly, Amgen, Roche, and Genentech. Dr Miller re-
ports being employed by and owning stock in Foundation Medicine,
Inc. Prof Pao reports owning stock in Roche and patients/royalties/
other intellectual property with MolecularMD. Dr Freiwald reports
being employed by Boehringer Ingelheim Pharma GmbH&Co.KG. Drs
Fan and Wang report being employed by Boehringer Ingelheim
Pharmaceuticals Inc. Dr Chand reports being employed by Boehringer
Ingelheim Pharmaceuticals Inc. until October 2015, and EMD Serono
Research & Development Inst. He also reports owning stock in BMS.
Prof Groen reports a consultancy/advisory role with Lilly, Roche, MSD,
and BMS and receipt of research funding from Boehringer Ingelheim,
Roche. The remaining author declares no conﬂict of interest.
Acknowledgments
This clinical research is funded by the sponsor, Boehringer
Ingelheim Pharmaceuticals Inc. Medical writing assistance, supported
ﬁnancially by Boehringer Ingelheim Pharmaceuticals Inc., was pro-
vided by Lynn Pritchard of GeoMed, an Ashﬁeld Company, part of UDG
Healthcare plc, during the preparation of this article.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the
online version, at doi:10.1016/j.lungcan.2017.08.014.
References
[1] M. Maemondo, A. Inoue, K. Kobayashi, et al., Geﬁtinib or chemotherapy for non-
small-cell lung cancer with mutated EGFR, N. Engl. J. Med. 362 (2010) 2380–2388.
[2] T. Mitsudomi, S. Morita, Y. Yatabe, et al., Geﬁtinib versus cisplatin plus docetaxel in
patients with non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial,
Lancet Oncol. 11 (2010) 121–128.
[3] T.S. Mok, Y.L. Wu, S. Thongprasert, et al., Geﬁtinib or carboplatin-paclitaxel in
pulmonary adenocarcinoma, N. Engl. J. Med. 361 (2009) 947–957.
[4] R. Rosell, E. Carcereny, R. Gervais, et al., Erlotinib versus standard chemotherapy as
ﬁrst-line treatment for European patients with advanced EGFR mutation-positive
non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase
3 trial, Lancet Oncol. 13 (2012) 239–246.
[5] L.V. Sequist, J.C. Yang, N. Yamamoto, et al., Phase III study of afatinib or cisplatin
plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mu-
tations, J. Clin. Oncol. 31 (2013) 3327–3334.
[6] Y.L. Wu, C. Zhou, C.P. Hu, et al., Afatinib versus cisplatin plus gemcitabine for ﬁrst-
line treatment of Asian patients with advanced non-small-cell lung cancer har-
bouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial,
Lancet Oncol. 15 (2014) 213–222.
[7] J.C. Yang, Y.L. Wu, M. Schuler, et al., Afatinib versus cisplatin-based chemotherapy
for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):
analysis of overall survival data from two randomised phase 3 trials, Lancet Oncol.
16 (2015) 141–151.
[8] C. Zhou, Y.L. Wu, G. Chen, et al., Erlotinib versus chemotherapy as ﬁrst-line
treatment for patients with advanced EGFR mutation-positive non-small-cell lung
cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3
study, Lancet Oncol. 12 (2011) 735–742.
[9] S. Kobayashi, T.J. Boggon, T. Dayaram, et al., EGFR mutation and resistance of non-
small-cell lung cancer to geﬁtinib, N. Engl. J. Med. 352 (2005) 786–792.
[10] W. Pao, V.A. Miller, K.A. Politi, et al., Acquired resistance of lung adenocarcinomas
to geﬁtinib or erlotinib is associated with a second mutation in the EGFR kinase
domain, PLoS Med. 2 (2005) e73.
[11] S.G. Wu, Y.N. Liu, M.F. Tsai, et al., The mechanism of acquired resistance to irre-
versible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients,
Oncotarget 7 (2016) 12404–12413.
[12] W. Pao, J. Chmielecki, Rational, biologically based treatment of EGFR-mutant non-
small-cell lung cancer, Nat. Rev. Cancer 10 (2010) 760–774.
[13] F. Solca, G. Dahl, A. Zoephel, et al., Target binding properties and cellular activity
of afatinib (BIBW 2992), an irreversible ErbB family blocker, J. Pharmacol. Exp.
Ther. 343 (2012) 342–350.
[14] K. Park, E.H. Tan, K. O'Byrne, et al., Afatinib versus geﬁtinib as ﬁrst-line treatment
of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a
phase 2B, open-label, randomised controlled trial, Lancet Oncol. 17 (2016)
577–589.
[15] T. Shimamura, H. Ji, Y. Minami, et al., Non-small-cell lung cancer and Ba/F3
transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the
dual-speciﬁc epidermal growth factor receptor and ERBB2 inhibitor HKI-272,
Cancer Res. 66 (2006) 6487–6491.
[16] S.E. Wang, A. Narasanna, M. Perez-Torres, et al., HER2 kinase domain mutation
results in constitutive phosphorylation and activation of HER2 and EGFR and re-
sistance to EGFR tyrosine kinase inhibitors, Cancer Cell 10 (2006) 25–38.
[17] D. Li, L. Ambrogio, T. Shimamura, et al., BIBW2992, an irreversible EGFR/HER2
inhibitor highly eﬀective in preclinical lung cancer models, Oncogene 27 (2008)
4702–4711.
[18] V.A. Miller, V. Hirsh, J. Cadranel, et al., Afatinib versus placebo for patients with
advanced, metastatic non-small-cell lung cancer after failure of erlotinib, geﬁtinib,
or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 ran-
domised trial, Lancet Oncol. 13 (2012) 528–538.
[19] M. Schuler, J.C. Yang, K. Park, et al., Afatinib beyond progression in patients with
non-small-cell lung cancer following chemotherapy, erlotinib/geﬁtinib and afa-
tinib: phase III randomized LUX-Lung 5 trial, Ann. Oncol. 27 (2016) 417–423.
[20] L. Regales, Y. Gong, R. Shen, et al., Dual targeting of EGFR can overcome a major
drug resistance mutation in mouse models of EGFR mutant lung cancer, J. Clin.
Invest. 119 (2009) 3000–3010.
[21] Y.Y. Janjigian, E.F. Smit, H.J. Groen, et al., Dual inhibition of EGFR with afatinib
and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and
without T790M mutations, Cancer Discov. 4 (2014) 1036–1045.
[22] National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology
(NCCN Guidelines®) for NSCLC V.3.2017.< https://www.nccn.org/professionals/
physician_gls/pdf/nscl.pdf > , 2017).
[23] D. Jackman, W. Pao, G.J. Riely, et al., Clinical deﬁnition of acquired resistance to
epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung
cancer, J. Clin. Oncol. 28 (2010) 357–360.
[24] J.E. Chaft, G.R. Oxnard, C.S. Sima, et al., Disease ﬂare after tyrosine kinase inhibitor
discontinuation in patients with EGFR-mutant lung cancer and acquired resistance
to erlotinib or geﬁtinib: implications for clinical trial design, Clin. Cancer Res. 17
(2011) 6298–6303.
[25] Common Terminology Criteria for Adverse Events v3.0, http://ctep.cancer.gov/
protocolDevelopment/electronic_applications/docs/ctcaev3.pdf, 2006.
[26] E.A. Eisenhauer, P. Therasse, J. Bogaerts, et al., New response evaluation criteria in
solid tumours: revised RECIST guideline (version 1.1), Eur. J. Cancer 45 (2009)
228–247.
[27] P.A. Jänne, J.C. Yang, D.W. Kim, et al., AZD9291 in EGFR inhibitor-resistant non-
small-cell lung cancer, N. Engl. J. Med. 372 (2015) 1689–1699.
[28] K. Park, J.S. Lee, K.H. Lee, et al., Updated safety and eﬃcacy results from phase I/II
study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung
cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI), J. Clin.
Oncol. 33 (2015) (abstract 8084).
[29] K.M. Quesnelle, J.R. Grandis, Dual kinase inhibition of EGFR and HER2 overcomes
resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance,
Clin. Cancer Res. 17 (2011) 5935–5944.
[30] Z. Watanuki, H. Kosai, N. Osanai, et al., Synergistic cytotoxicity of afatinib and
cetuximab against EGFR T790M involves Rab11-dependent EGFR recycling,
Biochem. Biophys. Res. Commun. 455 (2014) 269–276.
[31] K. Takezawa, V. Pirazzoli, M.E. Arcila, et al., HER2 ampliﬁcation: a potential me-
chanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers
that lack the second-site EGFR T790M mutation, Cancer Discov. 2 (2012) 922–933.
[32] Y.Y. Janjigian, C.G. Azzoli, L.M. Krug, et al., Phase I/II trial of cetuximab and er-
lotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib,
Clin. Cancer Res. 17 (2011) 2521–2527.
L. Horn et al. Lung Cancer 113 (2017) 51–58
58
